Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
| العنوان: | Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE) |
|---|---|
| المؤلفون: | Natalia V. Zhukova, Svetlana Protsenko, Rashida Orlova, Evgeniy V Ledin, David R Naskhletashvili, Alexey Viktorovich Novik, Svetlana A Tkachenko, Fedor Moiseenko, Kristina V. Orlova, Sergey V Gamaunov, Aleksandr I Kazmin, Igor Samoylenko, Victor L Chang, Natalia N. Petenko, Elena Karabina, Irina Zh. Shubina, Lev V. Demidov, Daniil Stroyakovskiy, Galina Kharkevich, Aleksandr N Yurchenkov, Ludmila V Vorotilina, Igor A Utyashev, Mikhail V. Volkonskiy, Anastasia S Vikhrova |
| المصدر: | Cancers, Vol 13, Iss 2529, p 2529 (2021) Cancers Volume 13 Issue 11 |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Article, Targeted therapy, BRAF, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, melanoma, 030212 general & internal medicine, dabrafenib, Vemurafenib, cobimetinib, RC254-282, Cobimetinib, Trametinib, trametinib, business.industry, Melanoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Dabrafenib, Retrospective cohort study, medicine.disease, MEK, Clinical trial, chemistry, 030220 oncology & carcinogenesis, chart review, vemurafenib, business, medicine.drug |
| الوصف: | Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response and survival rates. However, real-world data on treatment patterns and clinical outcomes for patients with advanced BRAF V600 mutant melanoma are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 patients with advanced BRAF V600 mutant melanoma, who received TT in a real-world setting and were not involved in clinical trials. The data were collected from twelve medical centers in Russia. The objective response rates (ORRs) to combined BRAFi plus MEKi and to BRAFi mono-therapy were 57.4% and 39.8%, respectively. The median progression-free survival (PFS) and median overall survival (OS) were 9.2 months and 22.6 months, respectively, for the combined first-line therapy 9.4 months and 16.1 months, respectively, for the combined second-line therapy and 7.4 months and 17.1 months, respectively, for the combined third- or higher-line therapy. Analysis of treatment patterns demonstrated the effectiveness of the combined TT with BRAF plus MEK inhibitors in patients with brain metastases, rare types of BRAF mutations, and across lines of therapy, as well as a well-tolerated and manageable safety profile. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6921260489f81e5cf67d124a56e8ccecTest https://www.mdpi.com/2072-6694/13/11/2529Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6921260489f81e5cf67d124a56e8ccec |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|